Skip to main content
. 2020 Jul 25;21:302. doi: 10.1186/s12882-020-01963-x

Table 1.

Characteristics of patients on hemodialysis or peritoneal dialysis

HD (n = 69) PD (n = 86) P Value
Age (years) 52.1 ± 13.3 54.2 ± 11.7 0.306
Dialysis vintage (months) 38.0 (12.0,75.0) 26.0 (12.8,58.0) 0.084
Male (n, %) 47 (68.1) 39 (45.4) 0.006*
DM (n, %) 17 (24.6) 36 (41.9) 0.028*
Primary causes of ESRD [n (%)]
 CGN 38 (55.1) 40 (46.5) 0.289
 DN 14 (20.3) 22 (25.6) 0.438
 CTIN 6 (8.7) 8 (9.3) 0.896
 HN 4 (5.8) 12 (14.0) 0.107
 Others 7 (10.1) 4 (4.6) 0.294
CVD in history, n (%) 19 (27.5) 21 (24.4) 0.621
BMI (Kg/m2) 22.64 ± 3.65 23.06 ± 3.60 0.476
Time-averaged test value
 Hb (g/L) 114.5 (111.0,116.4) 115.6 (110.9117.3) 0.345
 Alb (g/L) 40.1 ± 2.3 38.3 ± 2.9 < 0.001*
 cCa (mmol/L) 2.31 ± 0.34 2.38 ± 0.11 0.114
 P (mmol/L) 1.66 ± 0.37 1.56 ± 0.62 0.335
 iPTH (pg/ml) 170.6 (81.8363.2) 187.9 (107.8340.8) 0.615
 Scr (umol/L) 1043 ± 227 960 ± 273 0.078
 CRP (mg/L) 3.16 (1.53, 6.33) 2.44 (1.54, 4.53) 0.669
 LDL-C (mmol/L) 2.13 ± 0.58 2.97 ± 0.74 < 0.001*
 HDL-C (mmol/L) 0.92 (0.85, 1.09) 1.06 (0.93, 1.28) 0.006*
 T-Cho (mmol/L) 4.24 ± 0.81 5.17 ± 0.96 < 0.001*
 CRP (mg/L) 3.16 (1.53, 6.33) 2.44 (1.54, 4.53) 0.669
Medication use
 Calcium-based P bindera (n, %) 56 (100.0) 56 (88.9) 0.029*
 Non-calcium-based P binderb (n, %) 3 (5.3) 12 (19.1) 0.023*
 Cinacalcet (n, %) 2 (3.5) 1 (1.6) 0.918
 Vitamin D analogue (n, %) 29 (50.9) 15 (23.8) 0.002*
 Baseline CAC Score 97 (1744) 95 (0, 324) 0.361

*P < 0.05 Notes: CGN: chronic glomerulonephritis; DN: diabetic nephropathy; CTIN: chronic tubulointerstitial nephropathy; HN: hypertensive nephropathy; BMI: body mass index; Hb: hemoglobin; Alb: albumin; cCa: corrected calcium; P: phosphate; iPTH: Intact Parathyroid Hormone; ALP: alkaline phosphatase; CO2CP: carbon dioxide combining power; Scr: serum creatinine; UA: uric acid; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; T-Cho: total cholesterol; a, calcium carbonate; b, lanthanum carbonate or sevelamer